The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-up Exclusive Evaluation Option License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Tar Meta Biosciences, Inc. (``TarMeta'') located in King of Prussia, PA, USA.
Document
Prospective Grant of Start-up Exclusive Evaluation Option Patent License: “The Development and Use of Diazeniumdiolated and Hybrid Diazeniumdiolated Compounds for the Treatment of Ovarian Cancer in Humans”
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-up Exclusive Eva...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
82 FR 16406
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Prospective Grant of Start-up Exclusive Evaluation Option Patent License: “The Development and Use of Diazeniumdiolated and Hybrid Diazeniumdiolated Compounds for the Treatment of Ovarian Cancer in Humans”,” thefederalregister.org (April 4, 2017), https://thefederalregister.org/documents/2017-06545/prospective-grant-of-start-up-exclusive-evaluation-option-patent-license-the-development-and-use-of-diazeniumdiolated-an.